Vandetanib

Trade Name:

Caprelsa

Manufacturer/Distributor:

AstraZeneca

www.astrazeneca.ca 1-800-565-5877

Classification:

Receptor tyrosine kinase inhibitor (antineoplastic agent)

ATC Class:

L01XE12 - Vandetanib

Status:

active

Notice of Compliance (yyyy/mm/dd):

2012/01/12

Date Marketed in Canada (yyyy/mm/dd):

2012/01/24

Presentation:

Tablet: 100 mg. DIN: 02378582

Tablet: 300 mg. DIN: 02378590

Comments:

For treatment of progressive medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease.

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh Úxwumixw (Squamish Nation), and səl̓ílwətaʔ (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

British Columbia Drug and Poison Information Centre (BC DPIC)

Poison Information

Drug Information

Vandetanib

Follow DPIC